In a report released today, Do Kim from BMO Capital maintained a Buy rating on Constellation Pharmaceuticals Inc (NASDAQ: CNST), with a price target of $19. The company’s shares opened today at $10.45.
According to TipRanks.com, Kim is a 4-star analyst with an average return of 19.0% and a 57.5% success rate. Kim covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Akcea Therapeutics Inc, and Replimune Group Inc.
Constellation Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $19, implying an 81.8% upside from current levels. In a report issued on August 13, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $17 price target.
.
See today’s analyst top recommended stocks >>
Based on Constellation Pharmaceuticals Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $11.94 million. In comparison, last year the company had a GAAP net loss of $7.99 million.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CNST in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Constellation Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery, develeopment, and provision of biopharmaceutical products. It researches and develops small molecule therapeutics for the treatment of cancer, inflammatory and immunologic disorders. Its products include CPI-1205, CPI-0209, and CPI-0610.
